CliffBio
biologic

Lucentis

ranibizumab

Loss of exclusivityMarch 2030projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameLucentis
Active ingredientranibizumab
Strength6MG/ML (0.3MG/0.05ML)
Dosage formInjection
RouteIntravitreal
ModalityBiologic
FDA approvalMarch 2018
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lucentis patent cliff — loss of exclusivity March 2030 | CliffBio